Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
Year: 2006
Type: article
Institutions: Baylor College of Medicine, University of California, Los Angeles, Harvard University, National Institutes of Health, University of Colorado Health, University of Southern California, Children's Hospital Los Angeles, Children's National, University of Medicine and Dentistry of New Jersey, National Institute of Allergy and Infectious Diseases, Frontier Science & Technology Research Foundation, Inc., Social and Scientific Systems (United States), Progenics Pharmaceuticals (United States)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Health and Human Services, University of Southern California, Progenics Pharmaceuticals, Children's National Hospital, National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Center for Research Resources
Awards: CLINICAL TRIALS OF CD4 IGG2 AND HUMAB COMBINATIONS, G18691040, Pediatric Clinical Trials Program for AIDS, G2705502615, G2941572269, G3126028604, G3258243794, G3341501247, G3381016547, G348093950, Los Angeles Pediatric AIDS Clinical Trials Unit, G444342022, G4561803324, General Clinical Research Center, General Clinical Research Center, G5162579792, General Clinical Research Center, General Clinical Research Center, General Clinical Research Center, G6830587703, G686464379, Statistical/Data Management Center-Pediatric AIDS CTG, G760152555, Antibody-mediated protection against whooping cough, Philadelphia Pediatric AIDS Clinical Trials Unit, G868895564, Pediatric ACTG Coordinating and Operations Center, GENERAL CLINICAL RESEARCH CENTER, G9000056149, G9000174125, G9000190720, G908435047
OpenAlex ID: W1992332315